GLP-1 medications (semaglutide, tirzepatide) have reshaped the medical weight loss market — and the medspa is now the primary delivery point for many patients. Here's how to market medical weight loss at your medspa in 2026: compliant GLP-1 marketing, patient acquisition, body contouring bundle strategy, and retention.

The medical weight loss market has been restructured by a single category of drugs. GLP-1 receptor agonists — semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound) — have moved weight loss from the domain of bariatric surgery and long-haul lifestyle programs into monthly prescriptions that produce clinical results. The shift has been fast and enormous. And it has created a specific opportunity for medspas that is still largely uncaptured by most practices.

This post is a complete marketing guide for medspas offering medical weight loss in 2026. We cover compliance, patient acquisition, Google Ads, SEO, program pricing, and the high-value bundle strategy that turns a weight loss patient into a long-term aesthetic patient.

—

1. The Medical Weight Loss Moment: Why 2026 Is the Year for Medspas

GLP-1 medications did not just create a new treatment category. They reorganized the delivery infrastructure for weight loss medicine. Primary care physicians, overwhelmed with their panels, are not equipped to build the monitoring, nutrition coaching, and regular check-in frameworks these patients need. Bariatric centers are surgical in orientation. That leaves medspas and wellness clinics — practices already built around ongoing patient relationships, aesthetic results, and elective self-investment — as the natural home for the medical weight loss patient.

The numbers support this. The global GLP-1 market is projected to exceed $100 billion by 2030. Telehealth platforms (Hims, Ro, Found, Calibrate, Noom Med) rushed in and captured the low-touch, prescription-only segment early. But their model has a fundamental weakness: it is asynchronous, impersonal, and provides no in-office experience. Patients on maintenance — who have lost the weight and now face body composition questions, nutritional guidance needs, and aesthetic considerations — have nowhere to go within those platforms.

The local medspa wins on exactly the factors telehealth cannot replicate: in-person assessment, body composition monitoring, lab work interpretation, nutritional coaching, and the seamless integration of aesthetic treatments for the physical changes that weight loss produces. The local practice also wins on trust. A patient who has lost 35 pounds wants a provider who knows them, has their records, and can look at them — not a chat interface.

The competitive intensity is real. Telehealth has already commoditized the basic semaglutide prescription. Your competition is not primarily from other medspas — it is from $299/month platforms offering the same medication with no in-person touchpoint. That means your positioning must be clear: you are not selling the drug. You are selling the program.

—

2. GLP-1 Marketing Compliance: What You Can and Cannot Say

This is the section most practices get wrong, and the errors range from regulatory risk to ad account suspension.

FDA-Approved Language

Semaglutide and tirzepatide are FDA-approved for specific indications. Wegovy (semaglutide 2.4mg) is approved for chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity. Zepbound (tirzepatide) carries a similar indication. Ozempic and Mounjaro are approved for type 2 diabetes — prescribing them off-label for weight loss is legal but requires different marketing language.

Safe claim language: “medical weight loss program,” “weight loss injections,” “GLP-1 therapy for weight management,” “clinically supervised weight loss.”

Risky claim language: “cure obesity,” “guaranteed weight loss,” “lose X pounds in Y weeks,” specific outcomes tied to the medication by name without context.

Compounded vs. Branded Positioning

Compounded semaglutide and tirzepatide had a significant run while branded versions faced supply shortages. The FDA has moved aggressively to restrict compounding as supply normalizes — as of 2025, FDA stated that compounded semaglutide and tirzepatide are no longer on the shortage list, and compounders face enforcement risk. If your practice has been relying on compounded GLP-1 formulations, your marketing must not imply equivalence to branded versions, and you should have compliance counsel review your program language.

If you are prescribing branded products (Wegovy, Zepbound), you can reference those brand names in marketing — but you cannot make comparative efficacy claims or use before/after imagery that implies the drug alone produces the result.

Google Ads Policy

Google permits advertising for prescription medications in the US if the advertiser is a certified pharmacy or healthcare provider who has gone through Google’s verification process. Medspas advertising medical weight loss should pursue this certification. Without it, ads that reference prescription medications by name risk suspension.

What Google allows: ads for “medical weight loss program,” “weight loss consultation,” “medically supervised weight loss,” and clinic/practice landing pages that describe the program.

What triggers disapproval: language implying online pharmacy functionality, claims that are misleading about the medication, before/after imagery in the ad itself.

Meta Policy on Weight Loss Ads

Meta has specific restrictions on weight loss advertising. Before/after photos are prohibited in ads. Language that implies a negative body image or shames the viewer is prohibited. Ads that target users based on weight-related characteristics are restricted.

What works on Meta: educational content framed around health optimization, testimonial-style video (without before/after comparison), provider-forward content (clinician explaining the program), and retargeting audiences who have already visited your landing page.

—

3. Patient Profile: Who Seeks Medical Weight Loss at a Medspa

The telehealth platforms have captured the patient who wants the lowest-friction, lowest-cost prescription. Your patient is different.

The medspa medical weight loss patient is typically 35-60, has tried at least one prior weight loss method, has disposable income sufficient for a $400-600/month program, and is motivated by health optimization as much as appearance. They want someone to monitor their progress. They want labs reviewed by a provider who knows their case. They are often already a patient or prospect for your aesthetic services — or will become one after weight loss.

This patient explicitly does not want the telehealth experience. They have often tried it and found it impersonal or insufficient. They may have received a prescription with minimal follow-up and felt unsupported. They are seeking the in-person relationship.

This patient also has high lifetime value. A patient who achieves significant weight loss (20+ pounds) becomes a strong candidate for body contouring, skin tightening, and aesthetic rejuvenation — services they were not considering six months prior. The weight loss program is the acquisition vehicle for a multi-year aesthetic patient relationship.

—

4. Google Ads for GLP-1 and Medical Weight Loss

Keywords That Convert

CPCs in this category run $4–9, which is moderate for healthcare. Conversion rates on well-built landing pages run 8–15% for form fills or call clicks. At a $600/month program with average patient tenure of 6–9 months, even a $80–120 cost per lead is highly profitable.

Campaign Structure

Run separate campaigns for:

1. GLP-1/injection terms (semaglutide, tirzepatide, weight loss injections)
2. Program-level terms (medical weight loss program, medically supervised weight loss)
3. Competitor/telehealth comparison terms (telehealth alternative, in-person weight loss)

Use location targeting focused on a 10–15 mile radius around your practice. Include suburb-specific ad groups for surrounding communities.

Landing pages should be program-specific — not your homepage. A dedicated medical weight loss landing page with clear program description, pricing tier (or “starting at”), provider credentials, and a single CTA (book a consultation) converts 2–4x better than a general homepage.

—

5. SEO: Content That Ranks in the GLP-1 Vertical

The national telehealth platforms have strong domain authority but thin local pages. Local medical weight loss SEO remains significantly undercontested in most US markets.

High-Value Content Targets

• “[City] medical weight loss program” — local landing page
• “[City] semaglutide clinic” — service page
• “[City] tirzepatide treatment” — service page
• “Medical weight loss vs telehealth [comparison article]”
• “GLP-1 side effects what to expect [educational]”
• “How much does semaglutide cost [city]”
• “Body contouring after weight loss [city]”

The comparison content performs particularly well. A thorough article comparing in-person medical weight loss programs to telehealth platforms — written from the perspective of a practicing clinician — ranks well and converts visitors who are mid-decision.

Create individual service pages (not a combined “services” list page) for each treatment component: the initial consultation, lab work, medication management, nutrition coaching, and body composition monitoring. This supports both SEO and Google Ads quality scores.

—

6. Pricing and Program Structure

Market Benchmarks

Your medspa should be positioned at the standard-to-premium tier. Competing on price against telehealth is a race you will not win and a positioning you do not want.

Program Duration Structure

3-month program: Appropriate for initial trial patients or those close to their goal. Price slightly higher per month ($499–600) to reflect the overhead of setup and labs.

6-month program: The most common. Discount slightly vs. monthly ($449–550/month) to incentivize commitment. This is typically sufficient for 20–40 lb loss depending on medication and compliance.

12-month program: Best for patients with more significant weight goals or who want to include maintenance. Deepest discount ($399–499/month). Highest LTV. Include two full lab panels and a body composition assessment at month 6.

What to Include in a Complete Program

• Initial consultation and intake
• Initial and follow-up lab panels (metabolic panel, thyroid, HbA1c at minimum)
• GLP-1 medication management and prescription
• Monthly or biweekly provider check-ins (video or in-person)
• Nutrition coaching (even 2–3 sessions adds significant perceived value)
• Body composition monitoring (InBody or similar)
• Ongoing side effect management

Labs are a significant differentiator from telehealth. Most telehealth platforms do not monitor labs. The ability to say “we run labs, not just prescriptions” is a clear competitive advantage.

—

7. The Body Contouring Bundle: Converting Weight Loss Results

This is the strategic opportunity most medspas miss entirely.

A patient who has lost 25–40 pounds has a predictable set of aesthetic concerns: loose skin (abdomen, arms, inner thighs), reduced muscle definition, facial volume loss, and often changes in breast/chest contour. These are not hypothetical upsells — they are the natural next chapter of the weight loss journey that the patient is actively thinking about.

The clinical window for body contouring conversations is 3–6 months into a successful program, or at maintenance entry. Do not wait for the patient to ask. At their 3-month check-in, if they have lost 15+ pounds, introduce the concept: “As you continue toward your goal, many of our patients want to address skin tightening and body definition — would it be helpful to talk about what that might look like for you?”

Recommended Bundle Services

Create a formal “Body Transformation Package” that bundles weight loss program completion with a post-loss aesthetics assessment and introductory treatment package. Price the bundle at a modest discount (10–15%) to incentivize the transition from weight loss to aesthetics maintenance.

—

8. Retention: Converting Weight Loss Patients into Long-Term Aesthetic Patients

The medical weight loss patient who achieves their goal is at a pivot point. They have experienced what it feels like to invest in their body and see results. They are primed for continued investment in their appearance and health.

Your retention strategy should be explicit: the weight loss program is the entry point, not the destination.

The Maintenance-to-Aesthetics Bridge

At program completion or maintenance entry, schedule a “Next Chapter” consultation — separate from the weight loss check-in — to assess aesthetic goals. Frame it as a natural progression, not a sales conversation: “Now that you’ve hit your goal, let’s talk about what you want to maintain and what you want to enhance.”

Introduce a membership structure that covers both maintenance medication management and aesthetic services at a combined rate. Example: $299/month covers quarterly weight maintenance check-ins, quarterly labs, and 1 unit-based injectable treatment per month (Botox, dysport). This keeps the patient in a billing relationship with the practice and eliminates the decision friction of booking individual services.

Email and Retention Touchpoints

Weight loss patients should receive:

• Monthly check-in reminder (automated)
• Progress milestone acknowledgment at 10%, 20%, and goal achievement
• Educational content about body composition and aesthetic options (2x/month)
• Post-goal: aesthetic consultation offer at 30 days, 60 days, and 90 days post-goal

The 90-day post-goal window is the highest-converting moment for first aesthetic treatment. If a patient has not booked an aesthetic service within 90 days of completing their weight loss goal, they are at significant churn risk.

—

9. Differentiating From Telehealth Competitors

Your marketing must directly, clearly articulate what you offer that telehealth cannot. Do not be vague about this. Patients who are comparing you to Hims or Ro are doing so consciously, and they need specific reasons to choose in-person.

What Telehealth Cannot Provide

Your website, ads, and consultation materials should include a direct comparison. Patients respond to specificity. A landing page section titled “Why In-Person Medical Weight Loss Produces Better Long-Term Results” that walks through each of these differentiators will convert better than generic claims about “personalized care.”

—

10. Frequently Asked Questions

Q: Can I advertise semaglutide by name in Google Ads? A: You can, provided you complete Google’s healthcare provider certification. Without it, ads referencing prescription medication names risk disapproval or account flags. The certification process is worth completing — it takes 2–4 weeks but unlocks significantly more keyword and ad copy options.

Q: Our practice uses compounded semaglutide. How should we market the program? A: Focus your marketing language on the program, not the compound. “Medical weight loss program with GLP-1 therapy” is safer than “compounded semaglutide clinic.” Given the FDA’s enforcement posture on compounding, consult with your compliance attorney about how to position the program — and ensure your clinical protocols meet current guidance.

Q: How do we compete with platforms offering semaglutide for $199/month? A: You do not compete on price. You compete on program comprehensiveness, in-person support, lab monitoring, and the aesthetic integration that telehealth cannot offer. Position this explicitly. Your minimum program price should be $400+ because anything lower implies you are trying to match telehealth on cost — a battle you will lose.

Q: What metrics should we track for our medical weight loss program? A: Track program enrollment (monthly), patient retention at 3 and 6 months, average patient LTV (including downstream aesthetic treatments), cost per consultation, and consultation-to-enrollment conversion rate. Target 60–70% consultation-to-enrollment conversion for qualified leads.

Q: We’re concerned about GLP-1 side effects causing patient dissatisfaction. How do we handle this in marketing? A: Address this proactively. Patients who find out about nausea, constipation, or injection site reactions for the first time mid-program are more likely to drop out and leave negative reviews. Your intake materials, consultation, and onboarding should set realistic expectations. This is actually a marketing differentiator: “We prepare you for the full experience, not just the results.”

Q: Should we offer tirzepatide alongside semaglutide? A: Yes, if your prescribing provider is comfortable with both. Tirzepatide (Zepbound/Mounjaro) has demonstrated superior weight loss outcomes in clinical trials versus semaglutide. Offering both allows patient-specific protocol selection and positions your practice as clinically current. Market this as “personalized GLP-1 therapy” rather than defaulting to one medication for all patients.

—

Ready to grow your medical weight loss practice? Free 30-min strategy call — we’ll audit your current marketing and build a 90-day plan. Starts at $500/month.